Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
出版年份 2019 全文链接
标题
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
作者
关键词
-
出版物
OncoImmunology
Volume 8, Issue 4, Pages e1561120
出版商
Informa UK Limited
发表日期
2019-02-04
DOI
10.1080/2162402x.2018.1561120
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
- (2018) Masahiro Takeuchi et al. IMMUNOLOGY LETTERS
- High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
- (2018) Xiaofang Guo et al. Translational Oncology
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
- (2018) Neus Martinez-Bosch et al. Cancers
- PD-L1 Expression in Pancreatic Cancer
- (2017) Lei Zheng JNCI-Journal of the National Cancer Institute
- Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
- (2017) Xiuwen Lan et al. OncoTargets and Therapy
- PD-L1 Expression in Pancreatic Cancer
- (2017) Lei Zheng JNCI-Journal of the National Cancer Institute
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
- (2017) Audrey Benyamine et al. OncoImmunology
- Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
- (2016) Shang-Yi Huang et al. Oncotarget
- BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia
- (2016) Audrey Benyamine et al. OncoImmunology
- From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
- (2016) Paul R. Kunk et al. Journal for ImmunoTherapy of Cancer
- The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
- (2015) Katy K. Tsai et al. DRUGS
- Immune Therapy in GI Malignancies: A Review
- (2015) Judy Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
- (2015) Lai Mun Wang et al. Oncotarget
- BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
- (2015) Cara L Haymaker et al. OncoImmunology
- Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study
- (2014) Wanda K O’Neal et al. Journal of Translational Medicine
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection
- (2012) Murtada Alsaif et al. Proteomics Clinical Applications
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
- (2010) Laurent Derré et al. JOURNAL OF CLINICAL INVESTIGATION
- High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
- (2009) Hasni M’Hidi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now